Literature DB >> 18213473

Lipid-lowering drug use in Italian primary care: effects of reimbursement criteria revision.

G Trifirò1, M Alacqua, S Corrao, S Moretti, D U Tari, M Galdo, A P Caputi, V Arcoraci.   

Abstract

OBJECTIVE: To assess whether the prescribing pattern of lipid-lowering drugs (LLD) changed after reimbursement criteria revision in a general practice in southern Italy.
METHODS: From the Caserta-1 Local Health Service database, 93 general practitioners (GPs) who had consistently sent data about their patients during the years 2003-2005 were recruited. Prevalence of use and incidence of new treatments were calculated for each year, stratified by three drug cohorts: statins, omega-3 fatty acids, and fibrates. Subanalyses by gender, age, and indication of use were performed.
RESULTS: Overall, 1-year prevalence of LLD use increased from 2003 to 2004. After reimbursement criteria revision (November 2004), a slight decrease was observed for statins, from 41.1 (95% CI: 39.9-42.2) per 1,000 inhabitants in 2004 to 40.3 (39.2-41.5) in 2005, while omega-3 utilization fell markedly: 14.6 (13.9-15.3) vs. 5.4 (5.0-5.8). The use of both statins and omega-3 fatty acids was reduced particularly for primary prevention. On the other hand, utilization of statins increased in diabetic patients and as secondary prevention from 2004 to 2005. Concerning individual molecules, 1-year prevalence of use of any statin declined from 2004 to 2005, except for rosuvastatin.
CONCLUSIONS: Revision of reimbursement criteria led to significant changes in the trend in LLD use in general practice in southern Italy: (1) statin utilization was slightly reduced in 2005, although it increased in certain categories, such as diabetic patients, and (2) omega-3 fatty acid use was strongly reduced even though a higher use in postinfarction cases was reported.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213473     DOI: 10.1007/s00228-007-0459-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

Review 1.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

Authors:  P R Hebert; J M Gaziano; K S Chan; C H Hennekens
Journal:  JAMA       Date:  1997 Jul 23-30       Impact factor: 56.272

2.  European guidelines on cardiovascular disease and prevention in clinical practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Atherosclerosis       Date:  2003-11       Impact factor: 5.162

Review 3.  Omega 3 fatty acids and cardiovascular disease--fishing for a natural treatment.

Authors:  Jehangir N Din; David E Newby; Andrew D Flapan
Journal:  BMJ       Date:  2004-01-03

4.  Prescribing and taking medicines.

Authors:  Giselle Jones
Journal:  BMJ       Date:  2003-10-11

Review 5.  Safety of statins: focus on clinical pharmacokinetics and drug interactions.

Authors:  Stefano Bellosta; Rodolfo Paoletti; Alberto Corsini
Journal:  Circulation       Date:  2004-06-15       Impact factor: 29.690

6.  Should rosuvastatin be withdrawn from the market?

Authors:  Stefan R Florentinus; Eibert R Heerdink; Olaf H Klungel; Anthonius de Boer
Journal:  Lancet       Date:  2004 Oct 30-Nov 5       Impact factor: 79.321

7.  Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004.

Authors:  Gianluca Trifirò; Corrado Barbui; Edoardo Spina; Salvatore Moretti; Michele Tari; Marianna Alacqua; Achille P Caputi; Vincenzo Arcoraci
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

8.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

9.  Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting.

Authors:  A M Gotto; S M Grundy
Journal:  Circulation       Date:  1999-03-02       Impact factor: 29.690

10.  Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence?

Authors:  Isabelle Savoie; Arminée Kazanjian
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

View more
  11 in total

1.  Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009-2015.

Authors:  Rosarita Ferrara; Valentina Ientile; Vincenzo Arcoraci; Carmen Ferrajolo; Carlo Piccinni; Andrea Fontana; Salvatore Benvenga; Gianluca Trifirò
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

2.  Impact of reimbursement changes on statin use among patients with diabetes in Austria.

Authors:  Wolfgang C Winkelmayer; Markus Asslaber; Anna Bucsics; Thomas Burkhardt; Alexandra Schautzer; Peter Wieninger; Michaela Pogantsch; M Alan Brookhart
Journal:  Wien Klin Wochenschr       Date:  2010-02       Impact factor: 1.704

3.  Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011.

Authors:  Domenico Italiano; Annalisa Capuano; Angela Alibrandi; Rosarita Ferrara; Angelo Cannata; Gianluca Trifirò; Janet Sultana; Carmen Ferrajolo; Michele Tari; Daniele Ugo Tari; Margherita Perrotta; Claudia Pagliaro; Concita Rafaniello; Edoardo Spina; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 4.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

5.  Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study.

Authors:  Ylenia Ingrasciotta; Janet Sultana; Francesco Giorgianni; Andrea Fontana; Antonio Santangelo; Daniele Ugo Tari; Domenico Santoro; Vincenzo Arcoraci; Margherita Perrotta; Luisa Ibanez; Gianluca Trifirò
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

6.  The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis.

Authors:  Gianfranco Damiani; Bruno Federico; Angela Anselmi; Caterina Bianca Neve Aurora Bianchi; Giulia Silvestrini; Lanfranco Iodice; Pierluigi Navarra; Roberto Da Cas; Roberto Raschetti; Walter Ricciardi
Journal:  BMC Health Serv Res       Date:  2014-01-06       Impact factor: 2.655

7.  Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study.

Authors:  Cesare De Gregorio; Herbert Marini; Angela Alibrandi; Antonino Di Benedetto; Alessandra Bitto; Elena Bianca Adamo; Domenica Altavilla; Concetta Irace; Giacoma Di Vieste; Diego Pancaldo; Roberta Granese; Marco Atteritano; Salvatore Corrao; Giuseppe Licata; Francesco Squadrito; Vincenzo Arcoraci
Journal:  Nutrients       Date:  2017-06-07       Impact factor: 5.717

8.  The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy.

Authors:  Ylenia Ingrasciotta; Janet Sultana; Francesco Giorgianni; Achille Patrizio Caputi; Vincenzo Arcoraci; Daniele Ugo Tari; Claudio Linguiti; Margherita Perrotta; Andrea Nucita; Fabio Pellegrini; Andrea Fontana; Lorenzo Cavagna; Domenico Santoro; Gianluca Trifirò
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

9.  Pattern of statin use in southern italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?

Authors:  Carmen Ferrajolo; Vincenzo Arcoraci; Maria Giuseppa Sullo; Concetta Rafaniello; Liberata Sportiello; Rosarita Ferrara; Angelo Cannata; Claudia Pagliaro; Michele Giuseppe Tari; Achille Patrizio Caputi; Francesco Rossi; Gianluca Trifirò; Annalisa Capuano
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

10.  Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study.

Authors:  Claudia Giardina; Paola M Cutroneo; Eleonora Mocciaro; Giuseppina T Russo; Giuseppe Mandraffino; Giorgio Basile; Franco Rapisarda; Rosarita Ferrara; Edoardo Spina; Vincenzo Arcoraci
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.